Clopidogrel “resistance” and statin cotreatment – significant for cardiocoronary prevention in real life?

• References

• 1 Trip MD, Cats VM, van Capelle FJ. et al. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990; 322: 1549-54.
• 2 Grossmann R, Sokolova O, Schnurr A. et al. Variable extent of clopidogrel responsiveness in patients after coronary stenting. Thromb Haemost 2004; 92: 1201-6.
• 3 Müller I, Besta F, Schulz C. et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003; 89: 783-7.
• 4 Matetzky S, Shenkman B, Guetta V. et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-5.
• 5 Beckerath von N, Taubert D, Pogatsa-Murray G. et al. A patient with stent thrombosis, clopidogrelresistance and failure to metabolize clopidogrel to its active metabolite. Thromb Haemost 2005; 93: 789-91.
• 6 Järemo P, Lindahl TL, Fransson SG. et al. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 2002; 252: 233-8.
• 7 Gurbel PA, Bliden KP, Hiatt BL. et al. Clopidogrel for coronary stenting. Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-13.
• 8 Serebruany VL, Steinhubl SR, Berger PB. et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005; 45: 246-51.
• 9 Hochholzer W, Trenk D, Frundi D. et al. Ausmaß der Thrombozyteninhibition nach einer Initialdosis von 600 mg Clopidogrel und Prävalenz von Non- Respondern zum Zeitpunkt der Koronarintervention. Z Kardiol 2004; 93: P1384.
• 10 Taubert D, Kastrati A, Harlfinger S. et al. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost 2004; 92: 311-6.
• 11 Beckerath von N, Beckerath von O, Koch W. et al. P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose. Blood Coagul Fibrinolysis 2005; 16: 199-204.
• 12 Fontana P, Dupont A, Gandrille S. et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 2003; 108: 989-95.
• 13 Poulsen TS, Vinholt PM, Mickley H. et al. Existence of a clinically relevant interaction between clopidogrel and HMG-CoA reductase inhibitors? Reevaluating the evidence. Basic Clin Pharmacol Toxicol 2005; 96: 103-10.
• 14 Dai D, Tang J, Rose R. et al. Identification of variants of CYP 3A4 and characterization of their abilities to metabolize testosterone and chlopyrifos. J Pharmacol Exp Ther 2001; 299: 825-31.
• 15 Lau WC, Gurbel PA, Watkins PB. et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004; 109: 166-71.
• 16 Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed human cytochrome p450 3A and is inhibited by atorvastatin. Drug Metab Dispos 2003; 31: 53-9.
• 17 Hermann M, Asberg A, Christensen H. et al. Atorvastatin does not affect the pharmacokinetics of cyclosporine in renal transplant recipients. Eur J Clin Pharmacol 2005; 61: 59-62.
• 18 Lau WC, Waskell LA, Watkins PB. et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation. A new drug-drug interaction. Circulation 2003; 107: 32-7.
• 19 Vinholt P, Poulsen TS, Korsholm L. et al. The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease. Thromb Haemost 2005; 94: 438-43.
• 20 Gorchakova O, von Beckerath N, Gawaz M. et al. Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. Eur Heart J 2004; 25: 1898-2002.
• 21 Mitsios JV, Papathanasiou AI, Rodis FI. et al. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation 2004; 109: 1335-8.
• 22 Gum PA, Kottke-Marchant K, Poggio ED. et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001; 88: 230-5.
• 23 Gum PA, Kottke-Marchant K, Welsh PA. et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961-5.
• 24 Schwarz UR, Geiger J, Walter U. et al. Flow cytometric analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets – definition and detection of clopidogrel/ticlopidine effects. Thromb Haemost 1999; 82: 1145-52.
• 25 Barragan P, Bouvier J-L, Roquebert P-O. et al. Resistance to thienopyridines: Clinical detection of coronary stent thrombosis by monitoring of vasodilatorstimulated phosphoprotein phosphorylation. Cathet Cardiovasc Intervent 2003; 59: 295-302.
• 26 Aleil B, Ravanat C, Cazenave JP. et al. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular disease. J Thromb Haemost 2005; 3: 85-92.
• 27 Schrör K. Platelet reactivity and arachidonic acid metabolism in type II hyperlipoproteinemia and its modification by cholesterol-lowering agents. Eicosanoids 1990; 3: 67-73.
• 28 Piorkowski M, Weikert U, Schwimmbeck PL. et al. ADP induced platelet degranulation in healthy individuals is reduced by clopidogrel after pretreatment with atorvastatin. Thromb Haemost 2004; 92: 614-20.
• 29 Lim MJ, Spencer FA, Gore JM. et al. Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry. Eur Heart J 2005; 26: 1963-9.
• 30 Schrör K, Löbel P, Steinhagen-Thiessen E. Simvastatin reduces platelet thromboxane formation and restores normal platelet sensitivity against prostacyclin in type IIa hypercholesterolemia. Eicosanoids 1989; 2: 39-46.
• 31 Kaczmarek D, Hohlfeld T, Wambach G. et al. The actions of lovastatin on platelet function and platelet eicosanoid receptors in type II hypercholesterolemia. A double-blind, placebo-controlled prospective study. Eur J Clin Pharmacol 1993; 45: 451-7.
• 32 Miida T, Hirayama S, Nakamura Y. Cholesterol-independent effects of statins and new therapeutic targets: ischemic stroke and dementia. J Atheroscler Thromb 2004; 11: 253-64.
• 33 Undas A, Celinska-Lowenhoff M, Kaczor M. et al. New nonlipid effects of statins and their clinical relevance in cardiovascular disease. Thromb Haemost 2004; 91: 1065-77.
• 34 Cattaneo M. Aspirin and clopidogrel. Efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004; 24: 1980-7.
• 35 Niitsu Y, Jakubowski JA, Sugidachi A. et al. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin Thromb Hemost 2005; 31: 184-94.
• 36 Asai F. Jakubowski et al. A comparison of prasugrel (CS-747, LY640315) with clopidogrel on platelet function in healthy male volunteers. JACC 2005; 45 (Suppl. 01) 87A 868-8.
• 37 Wallentin L, Brandt JT. Inhibition of platelet aggregation with prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 receptor antagonist, compared with clopidogrel in aspirin-treated patients with atherosclerotic vascular disease. JACC 2005; 45 (Suppl. 01) 416A 1126-36.